当前位置:首页>产品中心>单抗/多抗>Anti-Human CD14 Reference Antibody|抗人CD14参考抗体(靶标:人CD14)

Anti-Human CD14 Reference Antibody|抗人CD14参考抗体(靶标:人CD14)

  • 货号:RB9THY038016
  • 价格:面议
  • 点击:652
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Chimeric
克隆性Monoclonal
抗体亚型IgG4-kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标Myeloid cell-specific leucine-rich glycoprotein, CD14, Monocyte differentiation antigen CD14
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号P08571
背景信息Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.
• Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis., PMID:34279540
• BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment., PMID:32544459
• Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS., PMID:36697826
• Presepsin for the Diagnosis of Neonatal Early-Onset Sepsis: A Systematic Review and Meta-analysis., PMID:35639395
• Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro., PMID:31573680
• Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans., PMID:32735845
• Mouse and human CD14 (myeloid cell-specific leucine-rich glycoprotein) primary structure deduced from cDNA clones., PMID:2472171
• Causal relationship between immune cells and epilepsy mediated by metabolites analyzed through Mendelian randomization., PMID:39179617
• Three distinct tolerogenic CD14+ myeloid cell types to actively manage autoimmune disease: Opportunities and challenges., PMID:33901801
• The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer., PMID:39187937
别名28C5, termed IC14, 2417175-94-9
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1784
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 1839
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 1733
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 1720
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 1660
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 1454
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 1773
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 1738
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 1721
Anti-Human CD42b/GP1BA Recombinant Antibody|抗人CD42b/GP1BA重组抗体(靶标:人血小板糖蛋白Ibα链/CD42b) 1830
Anti-Human JMJD1C Polyclonal Antibody|抗人JMJD1C多克隆抗体(靶标:人Jumonji结构域含蛋白1C) 1668
Anti-Human ITGB6 Polyclonal Antibody|抗人ITGB6多克隆抗体(靶标:人整合素β6亚基) 1910
Anti-Mouse IL33 Recombinant Antibody |抗小鼠IL33重组抗体(靶标:小鼠白细胞介素33) 1693
Anti-Mouse CD1d/CD1.1 Recombinant Antibody|抗小鼠CD1d/CD1.1重组抗体(靶标:小鼠CD1d分子) 1798
Anti-Mouse α5β1 (ITGA5 & ITGB1) Recombinant Antibody|抗小鼠α5β1(ITGA5和ITGB1)重组抗体(靶标:小鼠整合素α5β1复合物) 1835
Anti-Mouse VEGFA Recombinant Antibody|抗小鼠VEGFA重组抗体(靶标:小鼠血管内皮生长因子A) 1457
总计 33036 个记录,共 1652 页,当前第 1652 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30